...
首页> 外文期刊>Journal of the American statistical association >Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs
【24h】

Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs

机译:两阶段抽样设计下生存结果的时间相关精度测度的非参数最大似然估计

获取原文
获取原文并翻译 | 示例

摘要

Large prospective cohort studies of rare chronic diseases require thoughtful planning of study designs, especially for biomarker studies when measurements are based on stored tissue or blood specimens. Two-phase designs, including nested case-control and case-cohort sampling designs, provide cost-effective strategies for conducting biomarker evaluation studies.Existing literature for biomarker assessment under two-phase designs largely focuses on simple inverse probability weighting (IPW) estimators. Drawing on recent theoretical development on the maximum likelihood estimators for relative risk parameters in two-phase studies, we propose nonparametric maximum likelihood-based estimators to evaluate the accuracy and predictiveness of a risk prediction biomarker under both types of two-phase designs. In addition, hybrid estimators that combine IPW estimators and maximum likelihood estimation procedure are proposed to improve efficiency and alleviate computational burden. We derive large sample properties of proposed estimators and evaluate their finite sample performance using numerical studies. We illustrate new procedures using a two-phase biomarker study aiming to evaluate the accuracy of a novel biomarker, des--carboxy prothrombin, for early detection of hepatocellular carcinoma. Supplementary materials for this article are available online.
机译:对罕见的慢性病进行大规模的前瞻性队列研究需要对研究设计进行周密的计划,尤其是当基于存储的组织或血液样本进行测量的生物标志物研究时。两阶段设计,包括嵌套的病例对照和病例队列抽样设计,为进行生物标志物评估研究提供了具有成本效益的策略。有关两阶段设计的生物标志物评估的现有文献主要集中在简单的逆概率加权(IPW)估计器上。利用两阶段研究中有关相对风险参数的最大似然估计器的最新理论发展,我们提出了基于非参数最大似然估计器,以评估两种类型的两阶段设计下的风险预测生物标志物的准确性和可预测性。另外,提出了结合IPW估计器和最大似然估计程序的混合估计器以提高效率并减轻计算负担。我们导出拟议估计量的大样本属性,并使用数值研究评估其有限样本性能。我们使用两阶段生物标志物研究阐明了旨在评估新型生物标志物des-羧基凝血酶原用于肝细胞癌早期检测的准确性的新程序。可在线获得本文的补充材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号